FDA OTC vaginal antifungal products proposed class labeling announced July 16.
This article was originally published in The Tan Sheet
Executive Summary
FDA OTC VAGINAL ANTIFUNGAL PRODUCTS PROPOSED CLASS LABELING is intended to convey a "clear and consistent message" to the consumer, FDA explains in a draft guidance announced in the July 16 Federal Register. Current labeling for OTC vaginal yeast infection products "varies widely" among manufacturers, the draft notes, adding "in the OTC setting...consumers must have information that is easily understood to allow for appropriate self-selection and appropriate use of the product."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
People In Brief
Perrigo promotes in pricing, planning
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: